icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube

STUDY DESIGN

A randomised trial designed to identify which treatment options maximise efficacy whilst controlling toxicity below a certain threshold within each frailty stratum (fit, intermediate-fit and frail). 

CORRELATIVE STUDIES

TBA

TRIAL PRINCIPAL INVESTIGATOR

Professor Andrew Spencer

TIME FRAME

2019 – 2022

SITE LOCATIONS

  • TBA (Up to 30 sites)

PARTICIPANTS

300 newly diagnosed symptomatic multiple myeloma patients, 100 per frailty stratum 

CURRENT ENROLMENT

N/A

STATUS

Not Yet Open